Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Furkejuvvon:
Váldodahkkit: | , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Artihkal |
Giella: | eaŋgalasgiella |
Almmustuhtton: |
Philipps-Universität Marburg
2023
|
Fáttát: | |
Liŋkkat: | PDF-ollesdeaksta |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Lasit vuosttaš kommeantta. Visot kommeanttat leat almmolaččat.!